



MEDICAL  
UNIVERSITY  
OF WARSAW

## 25-hydroxyvitamin D concentrations before and in the first year of growth hormone treatment in relation to height velocity, IGF-1 and bone age

Ewelina Witkowska-Sędek, Beata Pyrżak, Magdalena Sagała, Anna Majcher, Anna Kucharska  
Department of Paediatrics and Endocrinology, Medical University of Warsaw

### Introduction:

The start of growth hormone (rhGH) treatment in children with growth hormone deficiency (GHD) causes a significant increase in bone turnover and increases height velocity. The increase in IGF-1 concentrations during rhGH treatment is a marker of the efficiency of treatment. Bone age delay at baseline is related to GHD and is a good predictor of height velocity during treatment. A significant increase in bone turnover during rhGH treatment results in an increased demand for vitamin D. It is important to determine proper supplementation doses of vitamin D in patients during catch-up growth.

### Aim of study:

The aim of the study is to evaluate the correlation between IGF-1, bone age and 25-hydroxyvitamin D at baseline and in the first year of rhGH treatment, and height velocity before and during rhGH treatment.

### Material and methods:

The study group consisted of 76 children aged 3–16 years with GHD. IGF-1 and 25-hydroxyvitamin D concentrations, bone age and anthropometric parameters were measured at baseline and during 12 months of treatment.

### Results:

Vitamin D status at baseline correlated with height velocity before rhGH treatment ( $p < 0.05$ ,  $r = 0.49$ ). The mean 25-hydroxyvitamin D concentration at baseline was 19.57 ng/ml ( $\pm 6.19$  SD) and after 12 months of rhGH treatment with vitamin D supplementation it increased to 24.1 ng/ml ( $\pm 6.88$  SD). A negative correlation between  $\Delta$  25-hydroxyvitamin D and  $\Delta$  IGF-1 ( $p < 0.05$ ,  $r = -0.38$ ) was found.

### Conclusions:

Vitamin D status is related to height velocity and adequate vitamin D supplementation is important in patients with GHD during catch-up growth, when their bone turnover is increased as a result of rhGH treatment. Determining proper supplementation doses of vitamin D in such cases requires further research.

$\Delta$  vitamin D vs.  $\Delta$  IGF-1 ( $p < 0.05$ ,  $r = -0.38$ )

